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Abstract The epidemiology of non-melanoma skin can-
cer (NMSC) is not well understood due to exclusion from
most US cancer registries. Patients with at least two claims
with a NMSC diagnosis (ICD-9-CM 173.xx) at least
60 days apart, or at least one claim for a NMSC-specific
treatment from 1/2010 to 12/2010, were identified from a
large US commercial insurance claims database and
grouped into one of three cohorts: metastatic (MET),
locally advanced (LA), or ‘‘all other’’. MET patients had at
least two claims with a metastasis code at least 30 days
apart. LA patients had at least two visits to a medical
oncologist, one diagnostic imaging service, two radiation
therapy services, or one visit to two or more physician
specialties. Remaining patients were ‘‘all other’’. Incidence
and prevalence of NMSC were calculated from among the
total number of persons continuously enrolled in the plan
during the study period and standardized to the 2010 US
population. From among 6,610,256 patients, there were
47,451 incident cases of NMSC (MET n = 16, LA
n = 387, all other n = 47,048). The age-adjusted inci-
dence rate of 693 per 100,000 persons (2010 population)
approximates to 2,139,535 total NMSC cases in the US
(0.7 % of population). 671 prevalent cases had advanced
disease (MET n = 43, LA n = 628); an age-adjusted rate
of 0.6 and 10 per 100,000 US persons equivalent to
1,993 and 29,841 MET and LA cases, respectively.
Although NMSCs rarely progress, the number of patients
with advanced disease is significant. Further studies to
determine proportions of advanced NMSC by subtype are
needed.
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Introduction
Non-melanoma skin cancer (NMSC) is the most common
cancer in the United States and is steadily increasing in
annual incidence. A limited number of publications exist
on the incidence and prevalence of NMSC due to exclusion
from US cancer registries. Rogers et al. [13] estimated that
2,152,500 persons in the United States were treated for
3,507,693 NMSCs in 2006. In the Medicare population, the
number of annual incident NMSC cases increased an
average of 4.2 % from 1992 to 2006 [13]. Incidence rates
are often highest for men and in the older age categories
[1–3], suggesting a cohort effect of increasing ultraviolet
exposure in successive, younger generations [2, 3]. NMSC
also poses significant burden to the US healthcare system.
Although mortality is low, the high volume of cases places
NMSC among the most costly of cancer malignancies. In
an analysis of Medicare billing claims in 1992–1995,
NMSC accounted for 4.5 % of the $13 billion spent on
cancer management [8].
The major subtypes of NMSC are basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC). Studies at the
local state level or ex-US registries estimate the proportion
of BCC patients to be 70–80 % and SCC patients to be
approximately 20 % of NMSC cases [1, 6, 9]. Less than
1 % of NMSC cases are other skin malignancies, including
Merkel cell carcinomas and various sarcomas. In a small
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subset of BCC patients, invasion to subcutaneous structures
can lead to locally advanced disease and may result in
substantial morbidity due to common BCC site locations
on the head and neck. Metastatic BCC is rare, with an
estimated incidence between 0.00281 and 0.5 % [11]. SCC
has a higher metastatic rate, with published estimates of
0.5–16 % [5]. Of the estimated 700,000 cases of SCC
diagnosed annually in the United States, approximately
2,500 result in death [14]. SCCs are at least twice as fre-
quent in men as in women [15], and occur mostly com-
monly in areas frequently exposed to ultraviolet rays [12],
but may occur on any area of the body [15]. Estimating the
exact incidence of BCC and SCC will be possible with the
histology-specific billing codes which became available in
October 2011 [4].
In an effort to better comprehend the epidemiology of
NMSC, this study characterizes the incidence and preva-




This study used administrative claims data from a large
national US managed care health plan affiliated with Op-
tum. The proprietary research claims database, the Optum
Research Database (ORD), contains data on commercially
insured and Medicare Advantage enrollees and includes
*14 million members annually. Member coverage is
diverse reflecting the geographic distribution of the
nationwide health insurer (12 % West, 23 % Midwest,
37 % South, and 29 % Northeast) and similar to the US
census age distribution for gender and age groups
\65 years [16]. The ORD includes demographic and
enrollment data, pharmacy claims, and medical claims that
provide data on services, procedures, and the accompany-
ing diagnoses. Medical claims include diagnosis codes
recorded with International Classification of Disease, Ninth
Edition, Clinical Modification (ICD-9-CM), procedures
recorded with ICD-9 procedure codes, current procedural
terminology (CPT) codes, or healthcare common procedure
coding system, and revenue codes.
The study data were de-identified and data were accessed
in accordance with the Health Insurance Portability and
Accountability Act [7] and, therefore, institutional review
board approval was not required for this study.
Patient selection
Commercial and Medicare Advantage health plan members
who had a diagnosis of NMSC or ‘‘other specified
(congenital) anomalies of the skin’’ captured by the ICD-9-
CM code 173.xx were identified from the ORD. To be
included in the final study sample, patients had to meet the
following inclusion criteria: (1) evidence of NMSC defined
as the presence of at least two claims with a diagnosis of
NMSC (ICD-9-CM 173.xx) in any position separated by a
minimum of 60 days from 01 January 2010 to 31
December 2010; OR at least one claim for a treatment
associated with skin cancer management and a diagnosis of
NMSC in the primary position on the same claim; (2)
continuous enrollment in either a commercial or Medicare
Advantage health plan during 2009 and 2010; (3) no evi-
dence of other primary cancers during the study period.
Diagnosis codes for other primary cancers included ICD-9-
CM codes 140.xx-172.xx, 174.xx-195.xx, 199.xx-209.xx.
The presence of at least two claims at least 60 days apart
with the same three-digit ICD-9 codes in any position was
considered evidence of an additional primary cancer.
From among the patients included in the study sample,
three mutually exclusive cohorts were identified: metastatic
NMSC patients (MET), locally advanced NMSC patients
(LA), and all others (DaCosta-Byfield S, Chen DM, Ra-
manan DD. Cost and patterns of care among patients with
advanced NMSC; ASCO Annual Meeting, June 3–7, 2011,
Chicago). MET NMSC patients had at least two claims, at
least 30 days apart, with a diagnosis for metastasis (ICD-9-
CM = 196.xx–198.xx) in any position during 2010. Since
stage of disease is not captured in claims data, an algorithm
based on clinical expert opinion attempted to capture
procedures and health care utilization associated with
NMSC patients who develop advanced disease. LA NMSC
patients had at least two claims with diagnosis code 173.xx
in any position for (1) medical oncology office visits or
outpatient visits on separate days, or (2) diagnostic imaging
services, or (3) radiation therapy on separate days, or (4) at
least one outpatient or office visit to two or more physician
specialties: medical oncology, radiation oncology, or oto-
laryngology (ENT). A diagnosis for lesion location on lip
(ICD-9 173.0), eyelid (ICD-9 173.1), ear (ICD-9 173.2),
face (ICD-9 173.3) or scalp, and neck (ICD-9 173.4) was
required on the same claim for the radiation oncology visit
and the otolaryngology visit. Any 173.x code could have
been on the claim for the medical oncology visit. Patients
who did not meet criteria for either the MET or the LA
population were considered to have early stage disease and
were categorized in the ‘‘all other’’ cohort.
Analysis
To determine incidence estimates during 2010, patients
with evidence of NMSC during 2009 were excluded. The
prevalence of advanced disease was determined from the
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frequency of patients with metastatic or LA disease in 2010
regardless of evidence of NMSC in 2009.
Age-adjusted incidence rates of NMSC and prevalence
of advanced disease were calculated per 100,000 persons
continuously enrolled in the health plan during 2009 and
2010, and standardized to the 2010 US population.
Results
From among the 6,610,256 health plan enrollees with
continuous enrollment from 1 January 2009 to 31
December 2010, a total of 68,782 patients had evidence of
NMSC during 2010 (Fig. 1). After excluding 7,731 patients
with evidence of other primary cancer, there were a total of
61,051 patients with evidence of NMSC during 2010.
Among these, 671 patients had evidence of advanced dis-
ease (MET n = 43 and LA n = 628) during 2010 and were
considered the prevalent population. In addition, a total of
47,451 patients had no evidence of NMSC during 2009 and
were considered incident cases (MET n = 16, LA
n = 387, all other n = 47,048).
Among the incident cases, the median age was 69 years
for the MET cohort, 74 for the LA cohort, and 64 for the
‘‘all other’’ cohort. As expected, most NMSC cases were
male and older in age, regardless of cohort (Table 1).
Among LA and MET patients, 85 and 95 %, respectively,
were 55 years or older. In addition, whether incident or
prevalent cases; more than 60 % of the LA patients were
Medicare advantage enrollees compared to less than half of
the MET patients, though the small sample size of meta-
static cases makes this difficult to interpret. Overall, the
distribution of both incident and prevalent patients in large
geographic regions of the Midwest, Northeast, South, and
West was similar to the distribution of enrollees in the
health plan overall, with the largest percentages of patients
residing in the South followed by the Midwest.
The age-adjusted incidence of NMSC (Table 2) overall
was 693 per 100,000 people standardized to the 2010 US
population, which is equivalent to approximately 2,139,536
NMSC cases (0.7 % of the US population). Incidence rates
of metastatic and locally advanced disease were 0.238 and
5.926 per 100,000 persons, equivalent to 734 (0.03 % of
cases) and 18,297 patients (0.9 % of US cases) in 2010,
respectively (Table 2). Incidence rates were highest among
individuals aged 75 years or older at a calculated rate of
208 per 100,000 persons.
A total of 671 prevalent NMSC cases with advanced
disease were detected in 2010 (MET n = 43, LA n = 628).
The age-adjusted prevalence was 0.645 and 9.665 per
100,000 people standardized to the 2010 US population
which is equivalent to 1,993 and 29,841 advanced NMSC
cases, respectively, in the United States in 2010.
Discussion
Although NMSCs, such as BCC and SCC, are the most
common skin cancers in the United States, their epidemi-
ology is poorly understood due to the lack of reporting in
US cancer registries. Furthermore, NMSC subtypes cannot
be accurately tracked because there are no ICD-9-CM
codes that uniquely classify BCC malignancies, SCC, or
‘‘other malignancies of the skin’’.
This retrospective study characterized the age distribu-
tion and epidemiology of NMSC patients and found that
Fig. 1 Sample selection and
attrition
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Table 1 Demographic characteristics of total enrollees and NMSC patients with continuous enrollment in 2009 and 2010
Total enrollees
(n = 6,610,256)

















n % n % n % n % n % n % n %
Age categories
0–17 1,433,250 22 37 \1 0 0 1 \1 36 \1 0 0 1 \1
18–24 445,109 7 57 \1 0 0 1 \1 56 \1 0 0 1 \1
25–34 797,610 12 551 1 0 0 0 0 551 1 0 0 0 0
35–44 1,063,028 16 2,761 6 0 0 14 4 2,747 6 0 0 17 3
45–54 1,174,338 18 7,935 17 1 6 33 9 7,901 17 1 2 49 8
55–64 896,985 14 12,572 26 6 38 61 16 12,505 27 16 37 94 15
65–74 427,895 6 10,673 22 3 19 86 22 10,584 22 8 19 140 22
75? 372,041 6 12,865 27 6 38 191 49 12,668 27 18 42 326 52
Male gender 3,214,386 49 25,888 55 11 69 222 57 25,653 55 36 84 391 62
Insurance
Commercial 6,001,709 91 31,436 66 10 63 147 38 31,277 66 24 56 235 37
Medicare advantage 608,547 9 16,017 34 6 38 240 62 15,771 34 19 44 393 63
Region
Northeast 692,892 10 4,428 9 3 19 42 11 4,383 9 5 12 64 10
Midwest 1,661,453 25 10,998 23 5 31 98 25 10,895 23 15 35 156 25
South 3,261,977 49 24,647 52 5 31 204 53 24,438 52 15 35 348 55
West 990,445 15 7,360 16 3 19 43 11 7,314 16 8 19 59 9
Other/unkown 3,489 \1 18 \1 0 0 0 0 18 \1 0 0 1 \1
Table 2 Rates of NMSC s during 2010












Ratea 95 % CI Ratea 95 % CI Ratea 95 % CI Ratea 95 % CI Ratea 95 % CI
Age categories
0–17 0.62 0.44–0.85 – – 0.02 0.00–0.09 – – 0.02 0.00–0.09
18–24 1.27 0.96–1.65 – – 0.02 0.00–0.12 – – 0.02 0.00–0.12
25–34 9.19 8.42–9.96 – – – – – – – –
35–44 34.55 33.26–35.84 – – 0.18 0.10–0.12 – – 0.21 0.12–0.34
45–54 98.50 96.33–100.67 0.01 0.00–0.07 0.41 0.28–0.58 0.01 0.00–0.07 0.61 0.45–0.80
55–64 165.62 162.72–168.51 0.08 0.03–0.17 0.80 0.61–1.03 0.21 0.12–0.34 1.24 1.00–1.52
65–74 175.42 172.09–178.75 0.05 0.01–0.14 1.41 1.13–1.75 0.13 0.06–0.26 2.30 1.92–2.68
75? 207.81 204.22–211.40 0.10 0.04–0.21 3.09 2.65–3.52 0.29 0.17–0.46 5.27 4.69–5.84
Total per 100,000 persons 692.977 0.238 5.926 0.645 9.665
Estimate of total persons with
NMSC in 2010 in the US
2,139,535 734 18,297 1,993 29,841
a Age-adjusted incidence per 100,000 people (standardized to the 2010 US population)
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incidence was approximately 0.7 %, which is equivalent to
2,139,536 NMSC cases in the US in 2010. This incidence
rate is consistent with the most recent published estimate of
2,152,500 patients treated for NMSC during 2006 [13]. As
in previous reports, incidence rates were highest in the
older age categories [1–3], and men were more often
diagnosed with NMSC. Among the incident NMSC cases,
0.03 and 0.9 % were metastatic and locally advanced,
respectively. Previously reported estimates of metastatic
disease have wide ranges from 0.0028 to 0.5 % for BCC
[11], and from 0.5 to 16 % for SCC [5]. The estimate for
the aggregate NMSC population in this study, is therefore
within range for BCC and low for SCC; however, this is
difficult to interpret since the proportion of BCC and SCC
in locally advanced and metastatic cases is not known. In
addition, SCC has a slightly higher metastatic potential
than BCC and likely constitutes greater than the estimated
20 % of NMSC once the disease progresses. Studies
investigating more precise estimates by unique skin cancer
diagnosis are warranted.
It must be noted that there are certain study limitations
associated with this study and with claims data, which are
collected for the purpose of payment and not research. In this
study, the indicated ICD-9 code (ICD-9-CM 173.xx) is not
specific for any of the NMSC skin cancers, but instead cap-
tures all NMSCs. However, BCC is known to be the most
common malignancy found in this category [6], accounting
for approximately 80 % of all newly diagnosed NMSC
cases. Second, the presence of a diagnosis code on a medical
claim is not positive presence of disease, as the diagnosis
code may be incorrect or may not precisely capture the
diagnosis of interest or the extent of disease. Metastatic
disease is likely under-reported in claims data given it is not a
requirement to precisely code primary versus secondary
malignancies. Further, since stage of disease is not captured
in claims data, an algorithm based on expert clinical opinion
and treatment guidelines, but not yet validated, was created
to characterize locally advanced versus metastatic and early
stage (‘‘all other’’) disease. In addition, the exclusion of
prevalent cancer patients with evidence of other cancers
during the study period (approximately 11 % of patients as
noted in the ‘‘Methods’’ Section), may underestimate the
cases of NMSC. Finally, the proportions of cases identified in
the claims data from a single health insurer may not be
generalizable to the entire US population. However, the
estimate of incident NMSC presented here is consistent with
previously published estimates [10, 13].
In summary, this study is among the few analyses that
attempt to characterize the epidemiology of locally
advanced and metastatic rates of NMSC. While the patient
population with advanced disease is relatively small, an
unmet medical need exists due to high morbidity and
limited therapeutic options. NMSC truly poses a public
health burden, as the annual number of incident NMSC
cases exceeds the combined total of annual incident cases
of colon, prostate, lung, breast, and prostate cancer. As
NMSC incidence rates continue to rise, it is likely that
occurrence of advanced disease will also increase. The
recent availability of BCC- and SCC-specific ICD-9 codes
in October 2011 warrants further research as it will enable
better characterization of the epidemiology of NMSC and
the histologic subtypes of BCC and SCC.
Acknowledgments The authors thank Victoria Porter, medical
writer at Optum, for her administrative and editorial assistance in the
preparation of this manuscript.
Conflict of interest The retrospective claims analysis described in
this paper was funded by Genentech, Inc. OptumInsight was hired by
Genentech, Inc. to conduct the analyses for this study. Three of the
authors (Diana Chen, Yeun Mi Yim, and Carolina Reyes) are
employed by Genentech, Inc., and the corresponding author (Stacey
DaCosta Byfield) is employed by Optum.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Athas WF, Hunt WC, Key CR (2003) Changes in nonmelanoma
skin cancer incidence between 1977–1978 and 1998–1999 in
Northcentral New Mexico. Cancer Epidemiol Biomarkers Prev
12:1105–1108
2. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R
(2007) Trends in incidence of skin basal cell carcinoma. Addi-
tional evidence from a UK primary care database study. Int J
Cancer 121:2105–2108. doi:10.1002/ijc.22952
3. Boi S, Cristofolini M, Micciolo R, Polla E, Dalla Palma P (2003)
Epidemiology of skin tumors: data from the cutaneous cancer
registry in Trentino, Italy. J Cutan Med Surg 7:300–305. doi:
10.1007/s10227-002-0135-0
4. Centers for Medicare & Medicaid Services (2011) New, Revised,
and Invalid Diagnosis and Procedure Codes FINAL VERSION –
Effective January 10, 2011. http://www.cms.gov/Medicare/Coding/
ICD9ProviderDiagnosticCodes/summarytables.html. Accessed 16
April 2013
5. Cherpelis BS, Marcusen C, Lang PG (2002) Prognostic factors
for metastasis in squamous cell carcinoma of the skin. Dermatol
Surg 28:268–273
6. Demers AA, Nugent Z, Mihalcioiu C, Wiseman MC, Kliewer EV
(2005) Trends of nonmelanoma skin cancer from 1960 through
2000 in a Canadian population. J Am Acad Dermatol
53:320–328. doi:10.1016/j.jaad.2005.03.043
7. Health insurance portability and accountability act of 1996.
Public law 104-191, 104th Congress (1996). http://www.
cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf
8. Housman TS, Feldman SR, Williford PM, Fleischer AB Jr,
Goldman ND, Acostamadiedo JM, Chen GJ (2003) Skin cancer is
among the most costly of all cancers to treat for the Medicare
population. J Am Acad Dermatol 48:425–429. doi:10.1067/
mjd.2003.186
Arch Dermatol Res (2013) 305:845–850 849
123
9. Katalinic A, Kunze U, Schafer T (2003) Epidemiology of cuta-
neous melanoma and non-melanoma skin cancer in Schleswig-
Holstein, Germany: incidence, clinical subtypes, tumour stages
and localization (epidemiology of skin cancer). Br J Dermatol
149:1200–1206
10. Lomas A, Leonardi-Bee J, Bath-Hextall F (2012) A systematic
review of worldwide incidence of nonmelanoma skin cancer. Br J
Dermatol 166:1069–1080. doi:10.1111/j.1365-2133.2012.
10830.x
11. Malone JP, Fedok FG, Belchis DA, Maloney ME (2000) Basal
cell carcinoma metastatic to the parotid: report of a new case and
review of the literature. Ear Nose Throat J 79(511–515):518–519
12. Marks R (1995) The epidemiology of non-melanoma skin cancer:
who, why and what can we do about it. J Dermatol 22:853–857
13. Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman
SR, Fleischer AB, Coldiron BM (2010) Incidence estimate of
nonmelanoma skin cancer in the United States, 2006. Arch
Dermatol 146:283–287. doi:10.1001/archdermatol.2010.19








16. Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C
(2012) Risk of mortality, fatal infection, and fatal malignancy
related to use of anti-tumor necrosis factor-alpha biologics by
rheumatoid arthritis patients. Semin Arthritis Rheum 42:223–233.
doi:10.1016/j.semarthrit.2012.05.004
850 Arch Dermatol Res (2013) 305:845–850
123
